BioCryst

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioCryst 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. 

CEO
Jon P. Stonehouse
CEOJon P. Stonehouse
Employees
580
Employees580
Headquarters
Durham, North Carolina
HeadquartersDurham, North Carolina
Founded
1986
Founded1986
Employees
580
Employees580

BCRX Key Statistics

Market cap
1.50B
Market cap1.50B
Price-Earnings ratio
-150.74
Price-Earnings ratio-150.74
Dividend yield
Dividend yield
Average volume
4.05M
Average volume4.05M
High today
High today
Low today
Low today
Open price
$7.44
Open price$7.44
Volume
0.00
Volume0.00
52 Week high
$11.31
52 Week high$11.31
52 Week low
$6.00
52 Week low$6.00

Stock Snapshot

With a market cap of 1.5B, BioCryst(BCRX) trades at $7.16. The stock has a price-to-earnings ratio of -150.74.

During the trading day, BioCryst(BCRX) stock saw an opening price of $7.44, a peak of —, and a bottom of —.

Trading volume for BioCryst(BCRX) stock has reached 0, versus its average volume of 4.05M.

Over the past 52 weeks, BioCryst(BCRX) stock has traded between a high of $11.31 and a low of $6.00.

Over the past 52 weeks, BioCryst(BCRX) stock has traded between a high of $11.31 and a low of $6.00.

BCRX News

Simply Wall St 2d
The Bull Case For BioCryst Could Change Following FDA Approval Of Pediatric ORLADEYO Pellets

BioCryst Pharmaceuticals has received FDA approval for an oral pellet formulation of once-daily ORLADEYO (berotralstat) to prevent hereditary angioedema attacks...

The Bull Case For BioCryst Could Change Following FDA Approval Of Pediatric ORLADEYO Pellets
TipRanks 3d
BioCryst’s Orladeyo Pediatric Approval and Strategic Expansion Drive Buy Rating

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on BioCryst. The associated price target was raised to $32.00. Claim 50% Off TipRanks Pr...

TipRanks 4d
BioCryst’s Avoralstat Study: A New Hope for Diabetic Macular Edema?

BioCryst Pharmaceuticals (BCRX) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fu...

Analyst ratings

90%

of 10 ratings
Buy
90%
Hold
10%
Sell
0%

More BCRX News

Simply Wall St 5d
Does BioCryst’s DCF and Sales Multiple Suggest a Bargain After Recent HAE Progress?

If you have been wondering whether BioCryst Pharmaceuticals at around $7.57 is a bargain or a value trap, you are not alone. This article is aimed squarely at t...

Does BioCryst’s DCF and Sales Multiple Suggest a Bargain After Recent HAE Progress?
Benzinga 6d
BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug

The U.S. Food and Drug Administration (FDA) on Friday approved BioCryst Pharmaceuticals Inc.’s (NASDAQ:BCRX) New Drug Application (NDA) for the use of an oral p...

TipRanks 6d
BioCryst Gains FDA Approval for Pediatric HAE Drug

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...

TipRanks 7d
BioCryst Announces Board Chair Transition Plan

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRank...

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.